Skip to main content
. 2014 Oct 2;10(10):e1004386. doi: 10.1371/journal.ppat.1004386

Figure 4. Removal of cross-reactive antibodies from primary DENV3-immune sera significantly protects AG129 mice from ADE-induced mortality.

Figure 4

Primary DENV3-immune human sera (DT118 and DT105) were depleted with heterotypic DENV2 virus (resulting in depletion of heterotypic anti-DENV1, DENV2 and DENV4 antibodies), transferred to AG129 mice 24 hours prior to administration of 2×105 pfu DENV2 (D2S10), and assessed for percent survival. ****Percent survival of virion-depleted DENV3 serum is significantly different from control-depleted DENV3 serum (p<0.0001). Data are pooled from three independent experiments using two primary DENV3-immune human sera.